DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

CYP2B6 Polymorphisms in Ketamine

Information source: Washington University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Volunteers

Intervention: ketamine (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Washington University School of Medicine

Official(s) and/or principal investigator(s):
Evan D Kharach, MD, PhD, Principal Investigator, Affiliation: Washington University School of Medicine

Overall contact:
Jane Blood, RN, Phone: 314-747-5531, Email: bloodj@anest.wustl.edu


This research study will determine if genetic variation in CYP2B6 affects how the body metabolizes ketamine.

Clinical Details

Official title: Role of CYP2B6 Polymorphisms in Ketamine Metabolism and Clearance

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome: The effects of CYP2B6 genetic variants on ketamine metabolism and clearance by CYP2B6*6 hetero or homozygote genotype.

Secondary outcome:

ketamine concentration

norketamine formation clearances and by genotype


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria: 1. 18-50 yr old 2. CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype (see table) (Note: subjects of other rare genotype but with one or more 516G>T, 785A>G, 983T>C or 1459C>T polymorphism may be enrolled at PI's discretion) 3. Good general health with no remarkable medical conditions 4. BMI <33 5. Provided informed consent Exclusion Criteria: 1. Known history of liver or kidney disease 2. Use of prescription or non prescription medications, herbals, foods or chemicals known to be metabolized by or affecting CYP2B6 3. Females who are pregnant or nursing 4. Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction) 5. Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)

Locations and Contacts

Jane Blood, RN, Phone: 314-747-5531, Email: bloodj@anest.wustl.edu

Washington University School of Medicine, St. Louis, Missouri 63110, United States; Recruiting
Evan D Kharasch, MD, PhD, Principal Investigator
Additional Information

Starting date: November 2013
Last updated: December 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017